Belvarafenib with cobimetinib for NRAS-mutant melanoma
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced melanoma that cannot be removed by surgery or has spread
- Your cancer has an NRAS gene mutation
- You have at least one tumor that can be measured on scans
- You are 19 years or older
- You have not been treated before with a RAF, MEK, or ERK inhibitor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
This Phase 1 trial tests a combination of targeted cancer medicines to treat melanoma that has spread or cannot be removed by surgery. It is for people whose tumor has a specific BRAF mutation, and who have either stayed stable on a prior targeted treatment or no longer respond to it.
This trial studies how doctors use encorafenib plus binimetinib for real-world care in people with BRAF V600–mutated melanoma that can’t be removed by surgery or has spread. It may help improve understanding of which patients benefit and what happens in everyday clinical practice.
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a personalized approach where doctors monitor tumor DNA in your blood to decide when to pause targeted therapy (encorafenib and binimetinib) for advanced melanoma with a BRAF mutation. The goal is to see if treatment breaks can be safe and effective.
Hear when a new Advanced or Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.